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Molecular Mechanisms of 33-mer Gliadin Peptide Oligomerisation 
María Julia Amundarain a, María Georgina Herrera†b, Fernando Zamarreñoa, Juan Francisco Visoa, 
Marcelo D. Costabel a# and Verónica I. Doderob# 
The proteolytical resistant 33-mer gliadin peptide is the immunodominant fragment in gluten and responsible for celiac 
disease, and other gluten-related disorders. Meanwhile, the primary structure of 33-mer is associated with the adaptive 
immune response in celiac patients, the structural transformation of 33-mer into protofilaments activates a primordial 
innate immune response in human macrophages. That means that accumulation, oligomerisation and structural 
transformation of 33-mer could be the unknown first event that triggers the disease. Herein, we reveal the early stepwise 
mechanism of 33-mer oligomerisation by combining multiple computational simulations, tyrosine cross-linking, fluorescence 
spectroscopy and circular dichroism experiments. Our theoretical findings demonstrated that the partial charge distribution 
along the 33-mer molecule together with the presence of glutamine that favours H-bonds between oligomers are the driving 
forces that trigger oligomerisation. The high content of proline is critical to forming the flexible PPII secondary structure that 
let to a β structure transition on oligomerisation. Experimentally, we stabilised the  33-mer small oligomers by dityrosine 
cross-linking, detecting from dimers to higher molecular weight oligomers, which confirmed our simulations. The relevance 
of 33-mer oligomers as triggers of disease as well as its inhibition may pose a novel therapeutic strategy for the treatment 
of gluten-related disorders. 
Introduction
The 33-mer gliadin peptide, LQLQPFPQPQLP69YPQPQLP76Y 
PQPQLP83YPQPQPF, is a proteolytical resistant fragment of 
gliadin, which is a dietary protein found in the gluten of wheat, 
rye, barley and some varieties of oats. 1, 2 The incomplete 
proteolysis of 33-mer in humans was demonstrated by an 
analysis of human stool and urine, of subjects under gluten-
containing diet, by using different ELISA methods. 3 It has been 
found that the 33-mer is the immunodominant peptide that 
triggers the adaptive immune response in celiac disease4, but 
the early events of the disease, as well as the role of 33-mer in 
other gluten-related disorders, remain elusive. 2, 5 Importantly, 
the 33-mer gliadin peptide self-assembles with a structural 
transition forming nanostructures and protofilaments under 
physiologically relevant conditions. 6, 7 Moreover, it was shown 
that a radiolabelled 33-mer metabolite was accumulated in 
different organs in murine models, detecting monomers and 
high order aggregates in vivo. 8 Recently, it was demonstrated 
that large 33-mer supramolecular structures activate the innate 
immune response via a Toll-like receptor (TLR) mechanism, 
evidencing the role of 33-mer oligomers as early triggers of the 
disease.9 In general, peptide/protein aggregates in combination 
with conformational transitions are the hallmark of misfolding 
diseases, including multiple sclerosis, Parkinson’s disease, HIV-
associated dementia, Alzheimer’s disease, and Huntington 
disease, among others. In such conditions, a whole spectrum of 
possible aggregate species display distinct sizes and shapes and 
exhibit various degrees of toxicity. 10-14 There is evidence that 
the early oligomers in the process of aggregation might be 
considered more toxic than mature species such as fibrils or 
plaques. 14, 15
Our hypothesis, in the context of gluten-related disorders, is 
that the persistence, accumulation, and oligomerisation of 33- 
mer per se might be an early event in the development of these 
diseases. Thus, any phenomenon inhibiting its oligomerisation 
may be considered as a possible new therapeutic target.  
Scheme 1. Hypothetical 33-mer gliadin peptide oligomerisation 
pathway based on the state of the art. 
Although the 33-mer high molecular weight (MW) oligomers 
are well characterised by electron microscopy, AFM, Helium 
microscopy and dynamic light scattering techniques, there is a 
lack of information about the initial stages of oligomerisation 
and its mechanism. 6, 7, 9, 
The main limitation is that 33-mer does not bind to any 
fluorescent dye, due to its high content of proline. Thus kinetic 
information of the early stages is not accessible by fluorescent 
detection methods.16 Furthermore, 33-mer oligomerisation 
depends mainly on peptide concentration, and so far, at low 
peptide concentration, there is no experimental evidence of the 
existence of 33-mer small oligomers before the nucleation step 
(Scheme 1). Thus, the initial oligomerisation pathway of 33-mer 
remains elusive.   
In the case of well-established amylogenic diseases, different 
modelling approaches were applied to their studies, such as 
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conventional molecular dynamic (MD) and replica-exchange, 
which have contributed to the understanding of the initial 
stages of oligomerisation for systems such as Aβ-42 peptide, 17 
Amylin 18 and the prion protein PrP106–126. 19  By a preliminary 
MD model, it has been shown that 33-mer can form a dimer.7 
The present work aims to gain an understanding of the early 
steps of the 33-mer oligomerisation process combining in silico 
and in vitro experiments. First, we employed computational 
methods which include analysis of electrostatic properties 
together with atomistic and coarse-grained MD simulations 
showing the feasibility of a stepwise oligomerisation 
mechanism. During the simulations, we detected that Tyr 69 
and Tyr 76 of two monomers are nearby less than 5Ǻ. Thus a 
cross-linking reaction was experimentally performed under 
physiologically relevant conditions, obtaining for the first time 
stable covalent 33-mer oligomers from dimers to higher 
molecular weight oligomers at the lowest concentration of 50 
µM, which is physiologically relevant.1 Altogether, we obtained 
theoretical and experimental evidence of 33-mer 
oligomerisation that is driven by the peptide non-ionic polar 
character, flexible PPII secondary structure and its stabilisation 
by glutamine H-bonds. 
Materials and Methods 
Computational protocol 
Model preparation and general protocol: The monomer model 
was prepared using the ABALONE software in a polyproline 
(PPII) structure, based on circular dichroism and nuclear 
magnetic resonance studies.20  
Initially, to evaluate the aggregation propensity of 33-mer 
monomers into oligomers of larger size, we performed two 
atomistic simulations with ten monomers randomly distributed 
in an aqueous solution. All the starting structures were created 
by taking into account that the peptides should not overlap 
(Table S1 –SI). No clashes were found using the criteria for 
contacts in Chimera (a distance of two Van der Waals radii plus 
0.4 Å). At the beginning of the production runs, it was 
corroborated that for every system, the interface between 
peptides/oligomers, was filled with water molecules.  Also, a 
coarse-grained simulation with the same starting configuration 
was included to assess the stability of the aggregates by another 
computational tool (SI). 
Finally, the stepwise aggregation of lower-order oligomers was 
assessed by atomistic MD simulations. Different starting 
configurations were assembled consisting of a monomer plus a 
lower order oligomer in different relative orientations. The 
distance between the peptides was initially at least as large as 
the sum of their Van der Waals radii and always consisted in 
elongated species (Table S2–SI). The electrostatic properties of 
the system were analysed, and from these results, hypothesis 
about the orientations that would favour aggregation was 
established and put into test through molecular dynamics 
simulations. We chose this approach to obtain oligomerisation, 
if possible, in accessible simulation times. In summary, MD 
simulations were performed assessing the behaviour of the 
peptides and oligomers in an aqueous solvent, by exploring 
their conformational space, and molecular patterns that favour 
oligomerisation. The detailed protocols are described below. 
Electrostatic interactions: It has been well established that 
electrostatic interactions play a fundamental role in the 
determination of stability and function of bio-macromolecules. 
21, 22 Therefore, an analysis of the electrostatic properties of the 
system was performed by solving the Poisson-Boltzmann (PB) 
equation, in all the structures to understand how these forces 
influence the self-organisation behaviour of the 33-mer 
peptide. The Adaptive Poisson-Boltzmann Solver (APBS) 
software package 23 was employed to solve the PB equation and 
model the electrostatic energy of interaction of the systems. 
This software solves the PB equation numerically by applying 
multigrid methods. In order to get the structures ready for the 
calculus and determine the protonation state of the peptides at 
physiological pH, PDB2PQR 24, 25 together with PROPKA 26, 27 
were used applying the force field PARSE. 28, 29 
The simulation temperature was 310 K, and an implicit solvent 
was used (the presence of the solvent is modelled as a 
continuum with an empiric dielectric constant). A dielectric 
constant of 2 was assigned for the lattice points lying within the 
peptide and 78.5 for those within the aqueous phase region. 
The ionic strength was represented through ion species with 
opposite charges (1 C and -1 C respectively) and atomic radii of 
2 modelled as 150mM of NaCl. Also, single Debye-Hückel 
boundary conditions were employed. The grid was determined 
for each system with the aid of APBS plug-in for Chimera, it was 
centred in the centre of mass of the system, and the length 
varied in such a way that the space between grid points was in 
average 0.49 ± 0.06 Å. The solutions of the PB equation 
obtained with APBS allowed us to construct maps of the 
equipotential surfaces and molecular surfaces coloured by 
potential. With the aid of the latter and careful visual 
inspection, hypotheses were made regarding the interacting 
regions. Additionally, the electrostatic profile of the monomer 
was analysed for pH 2, 7 and 9 (Table S3-SI). The different pH 
values are represented by changes in the protonation states of 
the residues, determined with PROPKA. 26, 27 
Molecular Dynamics: MD simulations have been used as a key 
tool to understand the mechanisms and the driven forces 
involved in the self-organisation process of many proteins and 
peptides. 30, 31 All the atomistic MD simulations were performed 
using GROMACS 4.6.5 package32, 33 and the standard united-
atom GROMOS53a6 force field. 34 The SPC/E model 35 was used 
for water molecules. Since the system is electrically-neutral, a 
concentration of 150 mM of NaCl ions was added. The 
protonation state of each amino acid is the one previously 
defined for pH 7 because it is the physiologically relevant pH. All 
the production simulations were carried out under the isobaric-
isothermal (NPT) ensemble with imposed 3D periodic boundary 
conditions. A time step of 2 fs and the Leap Frog algorithm were 
used for integrating the equation of motion. The Nose-Hoover 
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algorithm 36, 37 was employed to keep the temperature at 310 K 
for the production runs, using coupling constant tT=0.8 ps, and 
the Parrinello-Rahman barostat 38 to keep pressure isotropically 
constant at 1 bar, using a coupling constant tT=2.0 ps and 
compressibility 4.5 105 bar-1. Lennard-Jones interactions were 
cut off at a distance of 1.2 nm. For long-range electrostatics, the 
particle mesh Ewald (PME) method 39 was implemented with a 
real-space cut-off of 1.2 nm. LINCS algorithm 40 was applied to 
constrain all bonds to their correct lengths after an 
unconstrained update. The simulations were performed within 
a three-dimensional dodecahedral cell. The length of the box 
vectors was defined as the diameter of the system plus 2.8 nm; 
the detailed values for each system are presented in Table S2-
SI. 
To avoid the development of divergent forces, all the structures 
were minimised employing the steepest descent algorithm until 
the maximum force reached 200 kJ/mol.nm, with an initial step 
of 0.01 nm. Afterwards, a short simulation (200 ps) of the 
system in the NVT ensemble, at 310K, was performed while 
allowing the pressure to vary freely. The last equilibration step 
consisted of a 1 ns position restrained simulation in order to 
relax the solvent molecules around the peptides. For each 
system, 250 ns production runs were accomplished and then 
analysed with subprograms offered in the GROMACS package, 
namely g_rama (Ramachandran plots), g_rms (root mean 
square deviation), g_sas (solvent-accessible surface) and 
g_gyrate (radius of gyration). 
To find the representative structure of each oligomer, 
clusterisation of the trajectories was performed with GROMACS 
g_cluster, using the Linkage method with a variable cut-off 
according to the simulation under study.  
Possible hydrogen bonds were identified using geometric 
criteria, i.e., considering an acceptor-donor distance of 3Å and 
a cut-off for angles of 20 degrees, and selecting atoms that 
might act as donors and acceptors, as defined by Mills et al. 41 
The secondary structure was estimated with STRIDE algorithm 
implemented in VMD. 42 
Experimental Procedures 
Material:  
The 33-mer gliadin peptide LQLQPFPQPQLP69YPQPQLP76Y 
PQPQLP83YPQPQPF (3911 Da) with more than 95% purity was 
purchased to Biochem Shanghai Ltd lyophilised at different 
periods. Purity and mass were re-examined before 
experiments. Reverse-phase HPLC analysis was performed 
using a Venusil XBP C18 250 × 4.6. Binary gradients of solvents 
A (CH3CN 0.1 %TFA) and B (H2O 0.1%) were employed at a flow 
rate of 1.0 mL/min. The injection volume was 10 µL. HPLC peaks 
were detected by monitoring the UV absorbance at λ=220 nm, 
and the identity was confirmed by MS. The retention time of 
12.023 min was obtained under the following experimental 
conditions: CH3CN /H2O with 0.1% TFA, 28-100%A 25 min. HPLC-
MS (ESI): m/z 1958.61 (M+ + 2H) 2+, 1305.16 (M+ + 3H)3+. 
Accurate Mass determination has been performed by ESI nano-
MS: Measured Ion Mass (M+ + 4H)4+: 978.26472 (deviation 0.10) 
and Calculated Ion Mass: 978.26463 (deviation 0.11); Molecular 
Formula Obtained (C190H273N43O47) H4+4. 
Tyrosine Crosslinking of 33-mer peptide oligomers  
This experiment was performed to stabilise covalently the 
predicted in silico oligomers. The reaction was performed for a 
final peptide concentration of 50 µM in a total volume of 1 ml 
of 100 mM borate buffer pH 8.8 at 37°C. Briefly, the 33-mer 
gliadin peptide solution was prepared by taking an aliquot from 
a freshly prepared peptide stock solution in water and added in 
a borate buffer pH 8.8. Horseradish peroxidase Type VI (Sigma) 
was prepared in a stock solution in 10 mM phosphate buffer pH 
7.4 and added to the 33-mer solution in borate buffer to obtain 
a final enzyme concentration of 0.3 µM. The volume was 
completed with MilliQ, and the reaction was started adding an 
aliquot of hydrogen peroxide to obtain its final concentration of 
1 mM. Then, the reaction was maintained at 37°C for two hours 
and stopped adding a concentrated aliquot of Tris-Cl at pH 7.4 
(50 mM). 
Fluorescence Spectroscopy 
Emission spectra of tyrosine and dityrosine before and after the 
crosslinking reaction were acquired at 25 °C. For this purpose, 
the 50 µM of 33-mer gliadin peptide solution was excited at 274 
nm and 320 nm, tyrosine and dityrosine excitation maxima, 
respectively. For kinetic experiments, the sample was excited 
only at 320 nm, and the fluorescence emission spectra were 
recorded at 407 nm during 2 hours at 37°C. Experiments were 
performed in an FP-8300 fluorescence spectrometer from Jasco 
using bandwidth for the excitation and emission of 5 nm. 
Separation and analysis of cross-linked 33-mer oligomers by 
denaturant acrylamide electrophoresis 
The peptide solution was prepared at a final concentration of 
50 μM as explained above, taking samples at 10, 20, 30 and 1 
hour where the oxidative reaction was quenched with Tris.HCl 
pH 7.4 (100 mM). Then the samples were dissolved in urea at a 
final concentration of 8 M to disrupt other possible 
interactions and concentrated 50 times using an Amicon 
centricon with a cut off of 3kDa (Millipore). This protocol was 
perform to concentrate the sample and favour their detection. 
After this procedure, the sample was mixed with the sample 
buffer using 3.1 volume ratio, and subsequently, the resulting 
mixture was boiled for 5 min at 100 °C. The SDS 
electrophoresis analysis was performed using the Bio-Rad 
Mini-Protean chamber (Bio-Rad) under constant voltage (200 
V). The separation gel consisted of 10–20% Mini-PROTEAN® 
Tris-Tricine Gel, from Bio-Rad. Electrophoresis buffer for the 
cathode was 100 mM Tris-HCl, 100 mM Tricine, 0.1% (w/v) SDS 
at pH 8.3 and the anode buffer was 200 mM Tris-HCl at pH 8.9. 
The sample buffer composition was 8 % SDS, 20% glycerol, 10% 
2-mercaptoethanol, 0.002% Coomassie blue G250 and 100 mM 
Tris- HCl (pH 6.8). Two protein marker standards (BioRad) with 
a range of 1.400–26000 Da and 10000- 250000 Da were run 
alongside the samples. The gel was stained using a Zn staining 
protocol. 43  The gel analysis was performed using Image J, and 
the image montage was done with PhotoScape. 
Circular Dichroism: CD spectra of 50 μM of 33-mer gliadin 
peptide in 100 mM borate buffer pH 8.8 in the absence or 
presence of horseradish peroxidase (0.3 µM final 
concentration) were acquired in a Jasco-810 CD spectrometer 
using a Peltier system 















































































This journal is © The Royal Society of Chemistry 20xx 
Please do not adjust margins 
Please do not adjust margins 
ARTICLE 
as a temperature controller. The CD spectra of the 33-mer 
oligomers after the cross-linking reaction were also acquired. 
CD temperature dependent experiments were performed from 
-5°C, 10°C, 25°C and 37°C. Five scans were acquired in the 
range of 190–250 nm at a selected temperature with an 
incubation time of 5 min. A scanning speed of 50 nm per 
minute was applied, and 1 mm and 0.1 mm quartz cuvettes 
were used, for native oligomers and cross-linked ones, 
respectively. For all the experiments, the corresponding buffer 
solutions were analysed under the same conditions and 
subtracted from the sample spectra. Smooth noise reduction 
was applied using a Savitzky-Golay method. Graphics were 
represented using the program Origin (Originlab Software).
Results 
The in silico modelling of 33-mer oligomerisation propensity 
and structural transformation 
To explore the 33-mer oligomerisation propensity and 
conformational space of 33-mer oligomers, two different atomistic 
MD simulations of 10 monomers randomly distributed in water 
were performed (SI, Table S1-S2). Both initial conformations 
were unbiased. The units employed were obtained from the 
previously reported 33-mer monomer model with a polyproline II 
(PPII) motif.7 
In Figure 1, we present the 250 ns MD simulation, which converges 
after 50 ns to a stable decamer, as shown in the root-mean-square 
deviation (RSMD) plot. During the evolution of the simulation, it was 
observed a stepwise aggregation of the monomers into a decamer. 
During the first 50 ns of simulation, we detected an extended 
monomer, a dimer and heptamer (Figure 1B). Finally, these initial 
structures assembled into a stable decamer (representative 
snapshot Figure 1C). This process was evidenced in the solvent 
accessible surface (SAS) plot which displayed a marked decline in the 
exposed surface during the first 60 ns of the simulation and then a 
plateau which accounts for the stability of the newly formed 
aggregate (Figure 1D). The convergence of the simulation was 
corroborated with RSMD plot (Figure 1E). Taking a 0.30 nm cut-off, 
202 clusters could be formed for the simulation, with the largest 
cluster containing 81% of the total structures and an RMSD of 0.45 
nm between the most representative structure (Figure 1C) and the 
rest of the members of the group. 
The Ramachandran histogram showed that in the explored 
conformations, there was an increase of β-like content and decrease 
of the initial PPII motif (Figure 1F and Fig S1). The secondary 
structure per residue of the representative frame of the first 100 ns 
of the trajectory indicates that internal sequence 71QPQL has a 
conserved β secondary structure (between 60- 80%); meanwhile, 
83YP and the C-terminal F remain in PPII structure in the entire 
simulation (Fig. S2). 
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Both the intermediate states and the final oligomer displayed 
electrostatic potential and hydrophobic patterns compatible with 
further aggregation propensity. The final decamer is mainly 
hydrophilic, which justifies the formation of stable soluble oligomers 
in water (Figures 2 B-C). 6,7
To evaluate whether a different initial configuration would also 
reproduce aggregation, another MD simulation of 10 randomly 
oriented monomers at longer inter-peptide distances (for details see 
SI, Fig S3) was performed. This resulted in the aggregation, in less 
than 100 ns, of an octamer and two isolated monomers.  
To check the 33-mer oligomerisation propensity with a different 
computational molecular description, a coarse grained simulation 
was performed and described in the SI. In this simulation; a decamer 
was formed by the approach of the 33-mer monomers in the first 
nanoseconds of the entire 1 s production run (for details see SI, Fig 
S4). 
Altogether, these findings strongly suggest that the formation of 
stable high-order oligomers, such as decamers and hexamers are 
possible, and also that it is statistically feasible that monomers and 
dimers coexist with larger aggregates. Moreover, these results 
support our previous experimental observation that there is a 
conformational equilibrium between PPII and beta structure, 
favouring the formation of the later due to oligomerisation. 6, 7The 
detection of monomeric and dimeric species in the ten-monomer 
simulation motivated the study of the plausible stepwise 
oligomerisation of 33-mer. 
Evaluating the stepwise mechanism of 33-mer oligomerisation 
By this approach, the sequential formation of higher-order oligomers 
was studied (see Table S1 and S2). The electrostatic profiles of the 
33-mer monomer and the oligomers were analysed to identify the
regions with higher propensity to establish interactions with other
monomers. By this procedure, the starting configuration of each
ensemble was selected, and atomistic MD simulations were 
performed. In each simulation, the ensemble was generated by the 
addition of a monomer to the previous obtained oligomeric
structure.
The first analysis of the monomer showed that the electrostatic
potential of the peptide was not affected by changes in the pH (2,  7
and 9 values were analysed) (see Table S3). This is consistent with
the presence of non-ionic lateral chains in the peptide. For
physiological pH and PARSE force-field, the potential distribution on 
the molecular surface of the monomer is shown in Figure 2A.
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Figure 1. (A) Initial disposition of ten monomers in a solvated box depicted with licorice and the molecular surface coloured according to the electrostatic 
potential (measured in kBT/e) and the hydrophobicity (according to Kyte and Doolittle in cyan the more hydrophilic and in maroon the most hydrophobic 
residues). (B) The intermediate state of aggregation in which a monomer, a dimer and a heptamer evolve independently. (C) A representative structure of the 
principal cluster obtained from the atomistic MD simulation of the decamer. (D) The Solvent Accessible Surface area for the all-atom simulation of ten 
monomers displays four distinct regions, the first one represents the first assemblies of a heptamer and a dimer, the second one describes the evolution of 
these systems, the third stage shows how these three oligomers blend into one decamer which continues to increase its compactness in the latter region. (E) 
The RMSD evidences the stability of the oligomer after ~60 ns. (F) The Ramachandran histogram clearly shows two peaks in the PPII and beta regions. (G) The 
number of H-bonds during the trajectory is representative of the aggregation process.  
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This model evidenced 33-mer amphipathic nature, suggesting 
that the particular distribution of partial charges along the 
molecule in the PPII secondary structure is the intrinsic 
characteristic of 33-mer peptide that promotes its 
oligomerisation. The subsequent 250 ns MD simulation showed 
three stages of folding in which the peptide monomer remained 
mainly elongated for the first 20 ns (Fig. 2B-C) and then folded 
into increasing compact structures (Fig. 2D-E), as represented in 
the SAS plot (Fig. 2F). This behaviour suggested that it is possible 
that different monomeric species co-exist in equilibrium. 
The simulation converged after 100 ns (Fig. 2G). The dihedral angles 
adopted by the residues in the trajectory belong mainly to PPII and 
-like structures (Fig. 2H).  
Based on the probability of finding elongated monomers in the 
decamer simulation, two elongated peptides were selected to model 
the dimerisation. The electrostatic analysis of the interaction 
between two monomers showed that all the tested configurations 
had negative electrostatic energies of interaction. 
Figure 2. (A-E) Structural evolution of the monomer depicted with liquorice and through the molecular surfaces coloured by the electrostatic potential. Blue 
surfaces correspond to values 1kBT/e, white surfaces to 0 kBT/e and red surfaces to -1kBT/e Additional orientations are in Fig S6. (F) The Solvent Accessible 
Surface Area for the MD simulation is a measure of the packing of the structure; three distinct stages can be identified with different degrees of folding of the 
peptide (for the radius of gyration refer to Fig. S5). (G) The Root means square deviation shows the convergence of the simulation after 100ns. (H) 
Ramachandran histogram shows an increase in -like content in the final structure (see Fig. S16A).  
Thus, all of them could potentially form dimers. In order to promote 
aggregation, the configuration with the lowest electrostatic 
interaction energy was chosen. This was formed by two monomers 
oriented in an antiparallel fashion. This orientation had been 
observed in the second simulation of ten monomers (Fig S3). The MD 
simulations revealed that the dimer was formed after a few 
nanoseconds of the production run (Fig. 3A). The dimer remained 
elongated in the first part of the simulation, but then adopted a semi-
folded conformation (Fig. 3A and S7). This evolution is evidenced in 
the SAS graphic and radius of gyration shown in Figures 3A and S8, 
respectively. The production trajectory, which reached convergence 
after 200 ns, was clustered into 153 groups, of which only two 
contained 52% of the total structures. The biggest cluster contained 
31% of all the structures with an RMSD of 0.28 nm among the mean 
structure and the other members. This cluster represents elongated 
configurations. The second cluster, however, represents semi-folded 
conformations and contains 21% of the total structures, with an 
inter-cluster RMSD of 0.28 nm. These configurations are stabilized by 
several intra and inter-molecular H-bonds (see Tables S4-S5 and Fig 
S9).  
Following the same trend and motivated by the formation of a dimer, 
the aggregation into a trimer of an elongated monomer and the 
dimer in a stable conformation was assessed (Fig 3B). The initial 
configuration was based on electrostatic compatibility from visual 
inspection of the electrostatic potentials. During the MD simulation, 
the dimer and monomer rapidly approached each other to form an 
initial structure of a trimer. The SAS in Figure 3B is consistent with 
the visualisation of the trajectories, the RMSD and the gyration 
radius charts (Fig. S10 
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) 
 Figure 3. Molecular Dynamics Simulations and Analysis of the Secondary Structure of (A) Dimer, Trimer (B) and Tetramer (C), respectively. Top: Two Depictions 
of the most representative structures. The second corresponds to the molecular surface coloured by the electrostatic potential. Middle: Solvent accessible 
surface area and root-mean-square deviation through the MD simulation. Bottom: Ramachandran histogram of the trajectory of the corresponding 
simulations. (A) Dimer: The steep negative slope of the curve during the first nanoseconds represents the initial approach of the monomers and formation of 
a primitive dimer. It later evolves into a more compact structure but remains elongated for the rest of the simulation. The radius of gyration plot (Fig. S8) and 
additional orientations (Fig. S7) are in SI. (B) Trimer: Two steep negative slopes are observed at ~10 ns and ~30 ns. The first represents the aggregation of the 
trimer, while the second (smaller) represents an additional folding step. The radius of gyration plot (Fig. S10) and additional orientations (Fig. S11) are in SI. 
(C) Tetramer: The initial decrease corresponds to the formation of the tetramer, which is stable afterwards. The radius of gyration plot (Fig. S13) and additional
orientations (Fig. S14) are in SI.
The exposed surface decreased as a consequence of the aggregation 
process during the first nanoseconds, then it reached a 20 ns plateau 
representing the intermediate conformation with the monomer 
exhibiting a free end, and finally, there was a decrease in the SAS 
area produced by this end folding towards the rest of the structure. 
After that, the trimer remained overall stable and elongated (Fig. 
S11). The clustering process generated 60 groups; the largest 
contained 90% of the total structures with an average RMSD with the 
main structure of 0.22 nm. The representative structure of the most 
important cluster, which corresponds to 203 ns, is shown in Figure 
3B, and the H-bonds that stabilise such conformation are listed in 
Table S6, the evolution of the number of H-bonds is depicted in Fig 
S12. The overall shape is conserved after ~40ns. 
In the same way, the formation of a tetramer from the interaction 
between an elongated monomer and a trimer was analysed. The MD 
simulation showed a quick aggregation of the trimer and the 
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monomer, and then the structure of the new tetramer remained 
stable, as represented by the SAS plot, the RMSD (Figure 3C) and the 
radius of gyration (Figure S13). The production run was clustered into 
42 groups, the largest containing 58% of all the structures and an 
RMSD between the representative structure (152ns) and the 
remaining members of the cluster of 0.22 nm. This conformation of 
the tetramer (Figure 3C) was stabilised by several H-bonds (Figure 
S15 and Table S7) and remained unchanged for the rest of the 
simulation.  
Regarding the secondary structure for all the oligomers, the 
Ramachandran histograms showed that the residues scattered 
mainly in the regions corresponding to  structures and PPII (Figures 
2H, 3 A-C and S16). 
Only a couple of amino acids display at some point dihedral 
angles which describe alpha-helices, which is statistically 
correct since the probability of this combination happening is 
very low because of the high proline content of the peptide. It 
was also observed that the higher the oligomer, the higher is 
the role of glutamine in the formation of stabilised H-bonds 
(Tables S4-7). Experimentally, the 33-mer peptide, on increasing 
concentration, exists as a mixture of PPII structure and -
structures.6, 7  Here, we showed that during the MD simulations, 
the content of  structures increased, while the content of PPII 
decreased (from the starting monomer structure of 100% PPII) 
in all oligomers except in the tetramer in which they remain 
constant (Fig. S16). This difference can be explained by the 
already equilibrated content of both structures in the starting 
configuration of the tetramer. 
Dityrosine formation and stabilisation of 33-mer peptide 
oligomers at low concentration 
The 33-mer gliadin peptide presents in its sequence three 
tyrosine (Y) residues, LQLQPFPQPQLP69YPQPQLP76Y 
PQPQLP83YPQPQPF. In general, the tyrosine amino acid leads to 
the formation of radicals under oxidative conditions. 44 Under 
this circumstance, dityrosine bonds would be formed only when 
two tyrosine moieties are at a distance less than 5 Å. Therefore 
formation of dityrosine cross-links would probe the existence of 
33-mer small oligomers at a relevant physiological
concentration. 45-46 The new covalent C-C bond in the ortho-
ortho position of both phenolic groups of the tyrosine group is
a chemical tool employed to stabilise covalently low molecular
oligomers and protein intermediates. Furthermore, the
dityrosine formation process is associated with some
physiological processes such as in the formation of ligaments in
insects but also with pathological processes in
neurodegenerative diseases, atherosclerosis and ageing. 47-50
Interestingly, the dityrosine bond was found to be of key
importance in the formation of alpha-synuclein oligomers. 51,-52
In this regard, it is possible to monitor this transformation
because the dityrosine bond presents a characteristic
fluorescent signal at 407 nm when it is excited at 320 nm. Thus,
the new bond can be monitored in real-time by using
fluorescence spectroscopy. 53-55
Nevertheless, the formation of dityrosine bonds cannot be
reproduced through classic MD simulations; it is possible to
identify whether there are tyrosine groups that remain nearby
(< 5 Å) during the MD simulations (Fig. 4A-C, S17). After close
visual inspection of the contacts between tyrosine moieties of
the simulated structures, we observed that in the monomer, all
lateral tyrosine chains remained separated. On the contrary, the
dimer, trimer and tetramer displayed three tyrosines nearby,
which could potentially form a dityrosine bond, these are Tyr69
and Tyr76 from chain A and Tyr69 from chain B (Fig. 4A-B).
In addition to these tyrosines, the representative structure of
the decamer presents other position, more peripheral, that
includes Tyr69 of chain C and Tyr83 of chain D (Figure 4C).
Figure 4. During the process of oligomerisation in silico two Tyr69 from 
different chains, together with a Tyr76 from one of those chains moved 
closer, reaching distances between their CZ atoms of ~ 0.5 nm, which is 
consistent with the plausible stabilisation of the oligomers through dityrosine 
bonds. (A) The depiction of the three tyrosines in the representative 
conformation of the dimer and plot of the distance between CZ atoms of 
Tyr69 from chain A and Tyr69 from chain B. (B) Representation of the same 
tyrosine in the representative structure of the trimer. (C) Both probable sites 
for dityrosine bond formation for the decamer are depicted together with the 
evolution of the distances between their CZ atoms. 















































































This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 9
Please do not adjust margins 
Please do not adjust margins 
Journal Name 
The fact that the same assembly of tyrosines is observed in the 
dimer, trimer, tetramer and decamer, which were obtained 
from a different path, is suggestive of a conserved feature 
independent from the formation pathway. Taking into account 
these findings, we investigated the tyrosine cross-link of 33-
mer at a concentration where oligomers were not 
observable by DLS. 6 The reaction was catalysed by the 
enzyme horseradish peroxidase at 37°C. The first objective 
was to immobilise and therefore identify the predicted low 
molecular weight 33-mer oligomers and second to elucidate if 
there is, experimentally, a preference in size. Previous to 
the oxidative reaction, the individual tyrosine spectra 
showed an emission maximum at 303 nm, as presented in 
Figure 5A. After the reaction; there was a decrease in the 
intensity at the 303 nm maximum, while a new band at 407 
nm corresponding dityrosine was observed. Furthermore, 
the kinetics of the reaction was followed by exciting at 
320 nm, which is specific for dityrosine moiety. The maximum 
production of this bond occurred during the first hour (Figure 
5B), which was also corroborated by the characteristic 
emission spectra of the new dityrosine bond (Figure 5B inset). 
The size of the covalently linked 33-mer oligomers at 10, 20, 30 
minutes and 1 hour was obtained by SDS gel electrophoresis 
(Figure 5C, see Materials and Methods). It was detected that at 
10 and 20 minutes (lane 3 and 4, respectively), the main 
species in solution were monomer, dimers and trimers. 
However, after 30 minutes the presence of different oligomers 
from monomer to nonamers were detected; unfortunately, the 
corresponding band of the decamers (39110 Da) could 
not be detected because of the presence of the peroxidase 
which has the same MW (lane 5 and 6, respectively). These 
findings support our simulations and are indicative of a 
stepwise mechanism where different size oligomers co-
exist in equilibrium with the monomer previous the 
nucleation event. To obtain information about the secondary 
structure of the 33-mer oligomers before (t0) and after the 
cross-linking reaction (t2h), we performed temperature-
dependent circular dichroism experiments under both 
experimental conditions (Figure 6). Also, we corroborated that 
neither the presence of the enzyme nor the higher pH has a 
significant effect on the PPII secondary structure of 33-mer at 
the initial state (t0) (Fig. S18). 
Figure 5. Analysis of the formation of 33-mer peptide oligomers stabilised by dityrosine bonds at 50 μM final concentration, pH 8.8 in borate buffer. (A) 
Emission spectra of tyrosine obtained by exciting the sample at 280 nm, before () and after () the reaction. (B) Time-dependent assay of dityrosine formation 
followed by emission fluorescence at 407 nm. In the insert, it is presented the dityrosine emission spectra before () and after the reaction occurs (). In both 
experiments, the sample was excited at 320 nm. (C) Electrophoretic separation of 33-mer oligomers cross-linked by the formation of the dityrosine bond after 
different reaction times: 10 minutes (lane 3), 20 minutes (lane 4) and 30 minutes (lane 5) and 1 hour (lane 6). As controls, the 33-mer monomer without 
crosslinking (lane 1) and the horseradish peroxidase (lane 2) at the same concentration employed in the reaction and two different molecular weight markers 
were used. Analysis of the electrophoresis was performed and showed in the SI (Figure S19 and 20). 
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Figure 6. Circular Dichroism temperature-dependent experiments of 33-mer 
at 50 µM under crosslinking conditions. (A) At the initial time (t0). (B) After 
2h reaction (t2h). For details, see materials and methods section. 
Before the crosslinking reaction takes place, the 33-mer solution at 
50 µM has a negative band at 202 nm and a small positive band at 
228 nm at the lowest temperature of -5°C. This spectrum is 
characteristic of the PPII secondary structure (Fig. 6A). The PPII 
motif is characteristic of a negative band at around 200 nm and a 
small positive band at 220 nm, this last band is the signature of 
the PPII motif because it is absent in other secondary structures.56,57 
On the increasing temperature, the negative band became 
broad and shifted to 206 nm; meanwhile the 228 nm band became 
a negative shoulder. This behaviour was observed in and the 
33-mer at concentrations below 197 µM and in other PPII model 
systems. 7, 57,58 Also, there was a hypochromic behaviour of the band 
at 202 nm from -10300 to -7300 deg cm2 dmol-1, on increasing 
temperature from -5 to 37°C (Fig. 6A). The presence of one 
isodichroic point at 210 nm
implies that the 33-mer behaves as a two-state system in this 
temperature range. This experiment showed the loss of some PPII 
structure on increasing temperature, with an increase of the 
population of disordered states and/or the appearance of some 
small amount of β-structure, as observed before for native 33-mer 
and other model PPII peptides. 6, 7, 57, 58  
After the dityrosine crosslinking reaction, the 33-mer oligomers 
were covalently stabilised, and the system does not behave as a 
two-state system, as evidenced by the detected different 
isodichroic points (Fig. 6B). At the lowest temperature of -5°C, a 
negative band at 205 nm was observed with a value of molar 
ellipticity of 21600 deg cm2 dmol-1. Meanwhile, the value at 228 nm 
was nearly zero (-0.1600 deg cm2 dmol-1). Uversky has described 
that coil-like intrinsically disordered proteins (IDPs) that have 
substantial fractions of PPII helix displaying a molar ellipticity at 
around 200 nm of -19000± 2800 deg cm2 dmol-1 and -1700 ±700 
deg cm2 dmol-1 at around 222 nm which are similar to the values 
observed for the 33-mer covalently bonded. 59 It seems that the 
covalent ensemble of 33-mer stabilises the formation of PPII 
helices. 57, 58 On increasing the temperature to 37°C, the negative 
minimum band shift to 209 nm with a decreased of molar ellipticity 
to -17500 deg cm2 dmol-1, observing a broad negative shoulder in 
the region above 220 nm. The shift of the minimum from 205 to 
209 nm on increasing the temperature and the negative shoulder at 
220 nm are indicative of a PPII structure in equilibrium to β 
structure. The BESTSEL algorithm was employed to compare the 
percentage of β-structure of the 33-mer covalent oligomers 
at-5°C and 37°C (Fig. 6B. complete line). 60 By doing this, it was 
shown that the β strand component increase when increasing 
the temperature from -5°C to 37°C. The increment of the β 
anti-parallel structure was from 47.5% to 61.5% and for the β 
parallel from 0 % to 7.5%. This algorithm is not suitable to 
quantify PPII content. 60 
Discussion 
It is well-established that the primary structure of the 
proteolytical resistant 33-mer gliadin peptide may be relevant 
in the development of celiac disease and probably other gluten-
related diseases. In this regard, the role of 33-mer 
oligomerisation as a trigger of diseases in humans remains 
elusive. Nevertheless, it has been shown that the large 33-mer 
superstructures activate the innate immune response in human 
macrophages by a TLR 4 mechanism.9 Thus, the early steps of 
oligomerisation may be a novel therapeutic target to inhibit 
large oligomers formation thus avoiding the activation of the 
primary innate immune response. 
Herein, we investigated the 33-mer oligomerisation using a 
combination of computational and experimental methods. Due 
to the highly repetitive sequence of 33-mer, NMR experiments, 
under physiologically relevant conditions, are challenging. 
Previously in deuterated dimethyl sulfoxide (DMSO-d6), it had 
been shown that the 33-mer monomer has a PPII motif which 
was confirmed by CD spectroscopy. 4, 20  Later on, we showed 
that 33-mer secondary structure depends on concentration, 
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mainly due to the formation of different types of oligomers 
whose dimensions are from the nano- to the micrometer range. 
6, 7, 9 Experimentally, the self-assembly process of 33-mer 
peptides is highly dependent on its concentration as 
determined by circular dichroism and ATR-FTIR spectroscopy. 6, 
7 At low concentrations (between 6 and 50 μM), 33-mer exists 
in a conformational equilibrium between random and PPII 
secondary structure. Above 200 μM, the equilibrium shifts from 
PPII to parallel β-sheet structure.6, 7 Both techniques evaluate 
the secondary structure of the sample as a whole and do not 
provide molecular information. The PPII secondary structure is 
characterised by the dihedral angles φ=- 75 and ψ= 145 in the 
Ramachandran plot. 20, 57 This motif has been related to 
intermediate states of protein folding and superstructure 
formation because the PPII conformation is always in 
equilibrium with others structures like β-turns, β-strands and 
unordered conformations; due to the proximity of the 
respective dihedral angle values. 61, 62 In the absence of further 
structural information about 33-mer oligomers, the initial 
configuration of 33-mer and its oligomers were computationally 
modelled. We began the in silico evaluation of the 
oligomerisation process with the analysis of ten monomers 
embedded in water. The starting structures were in extended 
PPII conformation since this was suggested by previous in vitro 
experiments. 4, 20 The atomistic MD simulation of the ten 
monomers showed that one monomer remained half of the 
simulation isolated and elongated, and it was possible to detect 
co-existence with a dimer and a heptamer to finally evolve into 
a decamer with increased β-structure content. The MD 
simulation of the monomer showed that during the first 25 ns it 
evolved as a stable elongated structure and after that, it began 
a folding process which resulted in a more compact structure 
with high β structure content. These outcomes suggested that 
during the early events of oligomerisation, a mixture of 
monomers in folded and extended configurations is statistically 
possible. Moreover, we showed that the partial charge 
distribution of the 33-mer monomer is not affected for the pH, 
as expected due to its non-ionic polar character; which 
correlates well with previous experimental results. In order to 
assess the plausibility of formation of 33-mer oligomers by a 
stepwise mechanism, different MD simulations with atomistic 
detail, between monomers and nearby lower-order oligomers 
were evaluated. Theoretically, it is possible the oligomerisation 
into dimers, trimers, tetramers and oligomers of a superior 
order, like decamers. All the oligomers displayed similar 
characteristics consistent with the experimental information 
obtained in vitro: i.e. secondary structures with a high content 
of PPII secondary structure in equilibrium with  structures and 
amphipathic characteristics. Furthermore, we detected an 
increase of H-bond formation among glutamines on increasing 
complexity, 63 justifying the observed stabilisation of the high 
order oligomers in water experimentally (Table S2-5). 6, 7, 9 
The aggregation into oligomers of a superior order indicated 
that different structures could survive in dynamical equilibrium, 
including those with larger architectures, as detected 
experimentally for the 33-mer by the mentioned microscopic 
techniques. This behaviour was described for other amylogenic 
oligomers, too. 63-66
It is important to highlight that oligomerisation occurred for all 
the systems that were assessed. These results suggest that 33-
mer gliadin peptide should exist as an oligomer in solution. 
Importantly, the dityrosine bonds are only possible when 
tyrosine moieties are in proximity less than 5Å. Formation of 
covalently bond 33-mer dityrosine oligomers was confirmed by 
the formation of a new emission band at 407 nm specific for 
dityrosine bond and the decrease of the maximum emission 
signal of tyrosine. Also, the kinetics of the dityrosine formation 
was followed by the emission of dityrosine at 407 nm. The cross-
linked reaction reached the plateau after 1 hour. Furthermore, 
the MW of the 33-mer oligomers were determined by the 
electrophoretic separation under denatured conditions. The 
detection of monomers and oligomers of increasing MW from 
dimers to nonamers confirms the stepwise oligomerisation 
mechanism. As mentioned, the decamer could not be detected 
because of its similar MW with the peroxidase. We hypothesised 
based on our simulations that the dityrosine oligomers are formed 
through Tyr69 and Tyr76 as well as Tyr69 and Tyr83 of different 
monomeric chains.  
The secondary structure evaluation by CD shows that before 
dityrosine crosslinking the 33-mer at the concentration of 50 µM 
behaves as a two-state system with a significant PPII structure in 
equilibrium with other secondary structures like random or β 
structures. This behaviour was described before for the 33-mer at 
low concentration. 6, 7 After the dityrosine crosslinking reaction, the 
33-mer oligomers formed at 50 µM are covalently bonded, and the 
different size 33-mer oligomers remain stable in the buffer solution. 
Under this circumstance, the system increases its complexity, as 
shown for the different isodichroic points when the temperature 
increase. The PPII was detected as the main secondary structure at 
the lowest temperature tested, which then decreased its content in 
favour to β structures on increasing the temperature to 37°C. 
Interestingly, after cross-linking the covalent 33-mer ensemble 
showed a negative band at 205 nm, which is more than twofold 
relative to non-crosslinked system. We hypothesised that the 
formation of the Y-Y fixes the 33-mer in extended structures, thus 
considering the high content of prolines and glutamines of the 
system, the PPII helix is favoured. It is also accepted, that the PPII 
helices are favoured by intramolecular hydrogen bond from the 
glutamine side chain to the backbone carbonyl oxygen of the next 
residue of the sequence. 67 Taking into account that in the 33-mer 
sequence, the three tyrosine groups are located in the repetitive 
PYPQ sequence, it is highly probable that the new Y-Y favoured the 
mentioned intramolecular hydrogen bond. It seems that in the more 
flexible native 33-mer oligomers, intermolecular hydrogen bonds 
between the different interaction chains are favoured as obtained in 
the MD simulations.
The regular pattern of partial charge distribution along the peptide 
backbone obtained by MD shows the 33-mer amphiphilic nature of 
the monomer and oligomers even though the absence of ionic 
amino 
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acids. It is clear that the partial charge distribution on the 
monomer together with its flexible PPII structure is the driving 
force for the formation of the 33-mer oligomers. From the 
molecular point of view, the 33-mer peptide, 
LQLQPF(PQPQLPY)3PQPQPF, contains 65% of proline (P) and 
glutamine (Q), suggesting that hydrophobicity could be the 
driving force for self-assembly. Nevertheless, we found 
hydrophobic patches in the decamer; the main driving force is 
the electrostatic distribution along with the polar non-ionic 
structure. Also, on increasing oligomer size, the Q residues 
stabilise the oligomer structure via complementary hydrogen 
bonding. Q can link beta-strands together into beta-sheets by a 
network of hydrogen bonds between the amides from the 
backbone and the polar side chains, as detected in the MD 
simulation. 68 The importance of Q lateral chain in the formation 
of protofilaments has been highlighted in different amylogenic 
diseases, including Huntington’s disease.69 Finally, P is known to 
form loops, which can trigger oligomerisation. By our 
simulations, we detect that the internal sequence 71QPQL has a 
conserved β secondary structure. Thus, our simulations are meant 
to visualise the complementary partial charge distribution and 
rationalise the oligomerisation of the 33-mer peptide. Interestingly, 
dimerization as well as the formation of other oligomers, led to 
an increase of the polarisation of charge distribution along the 
new oligomer, facilitating further aggregation. The cross-linking 
experiment, together with our simulations showed that the 
stepwise mechanism is a feasible early oligomerisation pathway 
before the nucleation event (Scheme 2). 
Scheme 2. Schematic representation of the stepwise oligomerisation 
pathway of 33-mer gliadin peptide promoted by complementary partial 
charge distribution. 
The stepwise mechanism has been suggested for many homo-
oligomeric proteins, which show the modulation of their 
biological activities by adjusting their oligomeric states. 64-66, 70.
Taking into account that electrostatics interactions influence or even 
dominate initial biochemical reactions.71 The formation of different 
non-ionic polar 33-mer oligomers could potentially trigger different 
cellular responses. As observed microscopically, upon increasing 
peptide concentration, the interaction of different oligomers could 
lead to the nucleation step and formation of the 33-mer oligomers 
of a higher order. 6, 7, 9 We hypothesised that the propensity of 33-
mer to oligomerize could explain its enzymatic proteolytical 
resistance. We are aware that further theoretical and experimental 
methodologies are needed to dissect the mechanism of 33-mer 
oligomerisation. Thus the relevance of our findings justifies further, 
more sophisticated approaches.72, 73 Nevertheless, the trajectories 
showed an adequate sampling of the conformational space of each 
oligomer and provided the evidence that oligomerisation is 
statistically possible, as detected experimentally. Importantly, the 
atomistic simulations of 250 ns were sufficient to show the 
oligomerisation propensity with molecular detail. Furthermore, we 
validated the theoretical results experimentally using dityrosine 
crosslinking, isolating covalently bonded 33-mer small 
oligomers and detecting the presence of monomers, too. 
Conclusions 
In general, the combination of theoretical and experimental 
techniques in order to correlate molecular and supramolecular 
information is a clear win-win situation.74 Here, taking 
advantage of this fact, we employed this interdisciplinary 
approach to elucidate the mechanisms of oligomerisation of the 
immunogenic 33-mer gliadin peptide. We demonstrated the 
existence of soluble small 33-mer oligomers experimentally, 
providing molecular details. Based on our findings, we 
hypothesised that the stepwise oligomerisation process occurs 
as the first event before 33-mer nucleation. The existence of 
different non-ionic polar 33-mer oligomers in the cellular 
environment might explain the different and sometimes 
unrelated pathological conditions that are triggered by gluten 
consumption.1,2,5,8 Modulation of the early oligomerisation 
events may be crucial to delete the observed innate immune 
response triggered by the large 33-mer superstructures.9 
Therefore, inhibition of the early oligomerisation could be a 
novel therapeutic target. This report is a seminal contribution 
to disclose the role of 33-mer oligomers in gluten-related 
disorders at the molecular level. Finally, our report showed an 
unknown role of tyrosine to stabilise 33-mer small oligomers. 
Considering that oxidative conditions are a feasible 
environment in the inflammatory scenario. Thus, this plausible 
33-mer metabolite needs to be further investigated by other 
biophysical tools and in vivo.
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The 33-mer gliadin peptide oligomerizes driving by its non-ionic polar character, flexible PPII secondary structure and stable 
glutamine H-bonds.  















































































Table of Content Figure 
67x39mm (300 x 300 DPI) 
Page 16 of 16Physical Chemistry Chemical Physics
P
hy
si
ca
lC
he
m
is
tr
y
C
he
m
ic
al
P
hy
si
cs
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
is
he
d 
on
 2
3 
Se
pt
em
be
r 
20
19
. D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ita
t B
ie
le
fe
ld
 o
n 
9/
27
/2
01
9 
3:
38
:0
4 
PM
. 
View Article Online
DOI: 10.1039/C9CP02338K
